|
英汉对照(原创翻译) ,麻烦指正。
原文来自:medscape。
小细胞癌治疗方案
作者: Marvaretta M Stevenson, MD;
Treatment protocols for small cell lung cancer (SCLC) are provided below, including first-line therapy, therapy for limited-stage disease, and therapy for extensive-stage disease.
SCLC治疗方案见下,包括一线治疗、局限期治疗和广泛期治疗。
Treatment recommendations for limited-stage SCLC
Stages I-III disease:
局限期SCLC治疗推荐
I-III期
Limited-stage disease is typically treated with a combination of chemotherapy and radiation(concurrently)[1]
局限期的标准治疗是同步化放疗
Sequential therapy can also be given for limited-stage disease for patients unable to tolerate concurrent chemoradiation; chemotherapy is given first, followed by radiation therapy because of the high rate of responsiveness to chemotherapy for SCLC[2, 1]
若病人不能耐受同步化放疗则给予以下治疗:首先化疗,然后化疗,因为SCLC对化疗有较高的反应率。
T3-4 tumors due to multiple ipsilateral lung nodules are treated as extensive-stage disease[1]
Concurrent chemotherapy recommendationswith radiation for limited-stage diseaseinclude the following:
有多个同侧肺结节T3-4期肿瘤按广泛期治疗。
Cisplatin 60 mg/m2 IV on day 1 plus etoposide 120 mg/m2 IV on days 1-3 every 21d for 4 cycles[3]or
Cisplatin 80 mg/m2 IV on day 1 plus etoposide 100 mg/m2 IV on days 1-3 every 28d for 4 cycles[4]
顺铂60 mg/m2 IV d1 VP16 120 mg/m2 IV days 1-3 ,21天为1周期共4周期或
顺铂80 mg/m2 IV day 1 VP16 100 mg/m2 IV days 1-3 28天为1周期共4周期
Radiotherapy for limited-stage disease should start with cycle 1 or 2 of chemotherapy
局限期1或2个化疗周期后开始放疗。
Chemotherapy recommendations for patients not able to tolerate concurrent chemotherapy and radiation:
不能耐受同步化放疗者化疗的推荐
Patients with limited-stage (stages I–III) disease who are not able to tolerate chemotherapy and radiation concurrently should be treated with chemotherapy as first-line therapy
局限期(I–III期)不能耐受同步放化疗者化疗作为一线治疗
Cisplatin 60-80 mg/m2 IV on day 1 plus etoposide 80-120 mg/m2 IV on days 1-3 every 21-28d (maximum of 4 cycles)[3, 4]
顺铂60-80 mg/m2 IV day 1+VP16 80-120 mg/m2 IV days 1-3 ,每21-28d 为一疗程(最多4疗程)
Or或
Carboplatin AUC 5-6 IV on day 1 plus etoposide 80-100 mg/m2 IV on days 1-3 every 28d (maximum of 4 cycles)[5]
卡铂AUC 5-6 IV on day 1+VP16 80-100 mg/m2 IV on days 1-3,每28天为1疗程(最多4疗程)
First-line chemotherapy for extensive-stage disease
Stage IV disease:
广泛期一线化疗
IV期
The following treatment recommendations should be given for a maximum of 4-6 cycles:
下述推荐方案最多4-6疗程:
Cisplatin 60-80 mg/m2 IV on day 1 plus etoposide 80-120 mg/m2 IV on days 1-3 every 21-28d[6, 7, 8, 9, 10, 11, 12, 13]or
顺铂60-80 mg/m2 IV day 1+VP16 80-120 mg/m2 IV days 1-3 ,每21-28d 为一疗程
或
Carboplatin AUC 5-6 IV on day 1 plus etoposide 80-100 mg/m2 IV on days 1-3 every 28d[13, 14, 15, 16]or
卡铂AUC 5-6 IV on day 1+VP16 80-100 mg/m2 IV on days 1-3,每28天为1疗程
或
Cisplatin 60 mg/m2 IV on day 1 plus irinotecan 60 mg/m2 IV on days 1, 8, and 15 every 28d[8, 11, 12]or
顺铂60 mg/m2 IV on day 1+伊力替康60 mg/m2 IV on days 1, 8, 15,每28天为一疗程。
或
Cisplatin 30 mg/m2 IV on days 1 and 8 or 80 mg/m2 IV on day 1 plus irinotecan 65 mg/m2 IV on days 1 and 8 every 21d[7, 9]or
顺铂30 mg/m2 IV on days 1 ,8 或80 mg/m2 IV on day 1+伊力替康65 mg/m2 IV on days 1 ,8 ,每21d为一疗程。或
Carboplatin AUC 5 IV on day 1 plus irinotecan 50 mg/m2 IV on days 1, 8, and 15 every 28d[14, 16]or
卡铂AUC 5 IV on day 1+伊力替康50 mg/m2 IV on days 1, 8, 15 ,每28d为一疗程。或
Carboplatin AUC 4-5 IV on day 1 plus irinotecan 150-200 mg/m2 IV on day 1 every 21d[17, 18, 19]or
卡铂AUC 4-5 IV on day 1+伊力替康150-200 mg/m2 IV on day 1 ,每21天为一疗程。或[
Cyclophosphamide 800-1000 mg/m2 IV on day 1 plus doxorubicin 40-50 mg/m2 IV on day 1 plus vincristine 1-1.4 mg/m2 IV on day 1 every 21-28d[20, 21, 22]
环磷酰胺800-1000 mg/m2 IV on day 1+多柔比星40-50 mg/m2 IV on day 1+长春新碱1-1.4 mg/m2 IV on day 1,每21-28天为一疗程。
Second-line chemotherapy for relapsed or refractory disease
Stage IV disease[7] :
复发或难治性患者的2线化疗方案
IV期
Second-line chemotherapy is given for at least 4-6 cycles but can be given until disease progression as tolerated in some cases
2线化疗方案至少应用4-5周期;如果可以耐受也可以一直用至疾病进展
Patients who have relapsed disease more than 6mo after completing first-line chemotherapy can be treated with that original first-line regimen (typically a platinum-based doublet) again, with and expected response rate of 62-100%[2, 1]
完成一线化疗6各月后复发者可以再用原一线化疗方案(基础铂类加倍),预期反应率62-100%。
Etoposide 50 mg/m2 PO daily for 3wk every 4wk[23]or
VP1650 mg/m2 PO daily 共3周,每4周为一周期,或
Topotecan 2.3 mg/m2 PO on days 1-5 every 21d[24, 25, 26]or
托普替康2.3 mg/m2 PO on days 1-5,每21天为一周期。或
Topotecan 1.5 mg/m2 IV on days 1-5 every 21d[24, 25, 27]or
托普替康1.5 mg/m2 IV on days 1-5,每21d为1周期,或
Carboplatin AUC 5 IV on day 1 plus irinotecan 50 mg/m2 IV on days 1, 8, and 15 every 28d[14, 16]or
卡铂AUC 5 IV on day 1+伊力替康50 mg/m2 IV on days 1, 8,15。每28天一个周期,或
Carboplatin AUC 4 - 5 IV on day 1 plus irinotecan 150-200 mg/m2 IV on day 1 every 21d[17, 18, 19]or
卡铂AUC 4 - 5 IV on day 1+伊力替康150-200 mg/m2 IV on day 1,每21天一个周期,或
Cisplatin 30 mg/m2 IV on days 1, 8, and 15 plus irinotecan 60 mg/m2 IV on days 1, 8, and 15 every 28d[28]or
顺铂30 mg/m2 IV on days 1、8、15,+伊力替康60 mg/m2 IV on days 1、8、15 ,每28d一周期。或
Cisplatin 60 mg/m2 IV on day 1 plus irinotecan 60 mg/m2 IV on days 1, 8, and 15 every 28d[8, 12]or
顺铂60 mg/m2 IV on day 1+伊力替康60 mg/m2 IV on days 1、8、15,每28d一周期,或
Cisplatin 30 mg/m2 IV on days 1 and 8 or 80 mg/m2 IV on day 1 plus irinotecan 65 mg/m2 IV on days 1 and 8 every 21d[7, 9]or
顺铂30 mg/m2 IV on days 1 、8或80 mg/m2 IV on day 1+伊力替康65 mg/m2 IV on days 1 、8,每21天一周期。或
Paclitaxel 80 mg/m2 IV weekly for 6wk every 8wk[29]or
多西他赛80 mg/m2 IV 每周共6周,8周为一周期。或
Paclitaxel 175 mg/m2 IV on day 1 every 3wk[30]
多西他赛175 mg/m2 IV on day 1,每3周一周期。
Third-line chemotherapy for relapsed or refractory disease
Stage IV disease[1] :
难治或复发者的三线化疗方案
Etoposide 50 mg/m2 PO daily for 3wk every 4wk[23] or
VP16 50 mg/m2 每天口服共3周,每4周一个周期。或
Topotecan 2.3 mg/m2 PO on days 1-5 every 21d[24, 25, 26] or
托普替康2.3 mg/m2 口服on days 1-5 ,每21d为一周期。或
Topotecan 1.5 mg/m2 IV on days 1-5 every 21d[24, 25, 27] or
托普替康1.5 mg/m2 IV on days 1-5,每21d为一周期。或
Carboplatin AUC 5 IV on day 1 plus irinotecan 50 mg/m2 IV on days 1, 8, and 15 every 28d[14, 16] or
卡铂AUC 5 IV on day 1+伊力替康50 mg/m2 IV on days 1、8、15 ;每28d为一周期。或
Carboplatin AUC 4-5 IV on day 1 plus irinotecan 150-200 mg/m2 IV on day 1 every 21d[17, 18, 19] or
卡铂AUC 4-5 IV on day 1+伊力替康150-200 mg/m2 IV on day 1,每21d一周期。或
Cisplatin 30 mg/m2 IV on days 1, 8, and 15 plus irinotecan 60 mg/m2 IV on days 1, 8, and 15 every 28d[28] or
顺铂30 mg/m2 IV on days 1、8、15 +伊力替康60 mg/m2 IV on days 1、8、15 ,每28d一周期。或
Cisplatin 60 mg/m2 IV on day 1 plus irinotecan 60 mg/m2 IV on days 1, 8, and 15 every 28d[8, 12] or
顺铂60 mg/m2 IV on day 1 +伊力替康60 mg/m2 IV on days 1、8、15,每28d为一周期。或
Cisplatin 30 mg/m2 IV on days 1 and 8 or 80 mg/m2 IV on day 1 plus irinotecan 65 mg/m2 IV on days 1 and 8 every 21d[7, 9] or
顺铂30 mg/m2 IV on days 1、8 或80 mg/m2 IV on day 1 +伊力替康65 mg/m2 IV on days 1、8 ,每21d一周期,或
Paclitaxel 80 mg/m2 IV weekly for 6wk every 8wk[29] or
紫杉醇80 mg/m2 IV 每周一次,共6周,每8周一周期。或
Paclitaxel 175 mg/m2 IV on day 1 every 3wk[29]
紫杉醇175 mg/m2 IV on day 1,每3周一周期。
IRB-approved clinical trial
Special considerations
IRB—批准的临床试验
特别考虑
Patients with mixed SCLC/non-SCLC histology should be given the same treatment as patients with SCLC[1, 2]
小细胞和非小细胞混合组织类型按小细胞病人处理。
Prophylactic cranial irradiation is recommended for SCLC patients with a complete or partial remission (total of 25 Gy in 10 fractions or 30 Gy in 10-15 fractions)[1, 2]
达CR或PR的SCLC病人推荐预防性脑部放疗。
Dose dense or dose escalation chemotherapy regimens are not recommended outside of a randomized clinical trial[1, 2]
除非随机临床试验,不推荐剂量密度或剂量爬坡化疗方案。
Patients with brain metastases can receive chemotherapy prior to brain radiation due to high response rates with chemotherapy[1, 2]
脑转移者可先进行化疗然后进行脑部放疗,因为其对化疗有高反应率。 |
|